Access to the latest lab testing available on the market today
At WellcomeMD we are always on the lookout for new cutting edge lab tests and technology to share with our members. We encourage each and everyone of our physicians to take advantage of the many advances in treatment and technology on the market today, whether it’s new preventative screening or setting up a second opinion with one of the top treatment centers in the U.S.
We pride ourselves in offering our members healthcare that is more personal, pro-active, and effective. Below are advanced lab options now available to members of WellcomeMD. A discussion with your doctor will help you decide which tests may be right for you.
Screening for multiple cancers is now possible with Galleri®
With a single blood test, the Galleri multi-cancer early detection test screens for a cancer signal and predicts the tissue type or organ associated with the signal with one simple blood draw. The Galleri test screens for a signal shared by 50+ cancers, including fast-spreading, aggressive cancers that don't show symptoms, in early stages with a single blood test.
By adding the Galleri test to your cancer screening plan, you can increase your chance of finding cancer early. Here’s how it works:
Why the need for multi-cancer early detection?
Currently, only five types of cancer - colorectal, lung (for those at risk), breast, cervical, and prostate - have recommended screening tests that can identify cancer earlier.
Around 70% of cancer deaths are caused by cancers without recommended screening options. When cancer is caught early, before it has time to spread, the overall 5-year-cancer-specific survival rate is 4x higher than when cancer is diagnosed late.
Adding Galleri, a multi-cancer early detection test, to your cancer screenings allows you to go beyond what’s currently possible. Now you can screen for more than 50 types of cancer.
Who is Galleri for?
Did you know that cancer risk increases for everyone as they age regardless of family history. In fact, adults over the age of 50 are 13 times more likely to have cancer.
The Galleri test is recommended for adults with an elevated risk for cancer, and those aged 50 or older.
The Galleri test is not recommended in individuals who are pregnant, undergoing active cancer treatment or anyone 21 years old or younger.
The Galleri test is available by prescription only.
Talk to you WellcomeMD physician today to determine whether the test is right for you.
Talk to your WellcomeMD physician today to determine if the Galleri test is right for you.
Measure plaque build-up in the heart’s arteries with the Cleerly scan
Did you know every 1.7 seconds, a person dies from cardiovascular disease?
Cleerly measures atherosclerosis - plaque build-up in the heart’s arteries, offering personalized analysis and treatment of heart disease.
What is a Cleerly heart scan analysis?
The Cleerly analysis is a thorough evaluation of the presence, amount, and type of plaque in the heart’s arteries based on a heart scan, called a coronary computed tomography angiography (CCTA). The Cleerly scan can help facilitate early diagnosis, informed decision-making, and personalized treatment and tracking of coronary heart disease.
The results of the Cleerly analysis give a patient and their doctor a clear understanding of how much plaque (and which types) are in the arteries. This can be used by providers to assess the patient’s risk for heart attack and to provide personalized treatment recommendations, such as lifestyle changes and medication.
Cleerly’s approach is based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.
Why the need for early detection?
50% of people who suffer a heart attack will do so without experiencing symptoms
70% of heart attack victims are considered low risk by traditional methods of assessing heart disease
75% of lesions responsible for heart attacks only cause mild narrowing of the arteries and are missed by conventional stress testing
Who should take the Cleerly scan?
Cleerly is available for individuals who have symptoms of heart disease or believe they are at risk of coronary artery disease, but do not have symptoms.
If you are currently exhibiting chest pain, current guidelines recommend CCTA as a test for evaluation of chest pain. Cleerly is a new heart test and is not fully covered by insurance. Please talk to your WellcomeMD provider today to determine if the Cleerly scan is right for you.
Second Opinion Pathology Consultations with MDAnderson
Cancer treatment therapies are advancing rapidly. Tissue biopsy is not only necessary in confirming a cancer diagnosis but also plays a critical role in determining the most appropriate treatment. The pathologist’s evaluation of the tissue is pivotal to ensuring you have the best opportunity for survival. In certain situations, you may need a second opinion or second review of the biopsy. One option is a second opinion pathology consultation through one of the top cancer treatment centers in the US, MDAnderson.
Getting a second opinion can help you choose the most effective treatment.
MD Anderson has experts in a wide range of cancer subspecialties, including:
Breast
Dermatopathology
Gastrointestinal
Genitourinary
Gynecologic
Head and neck
Neuropathology
Bone and soft tissue
Thoracic
